2 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 2, Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies blood sampling, Nivolumab - Metastatic Melanoma | Phase 4 | Completed | Hospices Civils de Lyon | 32 | 2015-04-23 | 2025-09-15 |
| HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma High Dose Interleukin-2, Ipilimumab - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 29 | 2013-05-01 | 2023-12-05 |
| HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma vemurafenib + HD IL-2 - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 53 | 2012-08-01 | 2021-02-01 |
| Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Aldesleukin - Metastatic Renal Cell Carcinoma, Metastatic Melanoma | Phase 4 | Completed | Novartis Pharmaceuticals | 26 | 2008-09-03 | 2021-06-08 |
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Cisplatin, Vindesine, Dacarbazine (drugs) - Metastatic Melanoma | Phase 4 | Unknown | Dermatologic Cooperative Oncology Group | 200 | 2001-09-01 | 2006-06-21 |
Melanoma (7) · Neoplasm Metastasis (3) · Skin Neoplasms (3) · Carcinoma, Renal Cell (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neuroendocrine Tumors (7) · Nevi and Melanomas (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Skin Neoplasms (4) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Adenocarcinoma (2)
aldesleukin (3) · Nivolumab (2) · Blood Specimen Collection (1) · Cisplatin (1) · Dacarbazine (1) · Immune Checkpoint Inhibitors (1) · Interleukin-2 (1) · Interleukins (1) · Ipilimumab (1) · Pharmaceutical Preparations (1) · Specimen Handling (1) · Vemurafenib (1) · Vindesine (1) · relatlimab (1)
Clinigen, Inc. (2) · Bristol-Myers Squibb (1) · Dermatologic Cooperative Oncology Group (1) · Hospices Civils de Lyon (1) · Novartis Pharmaceuticals (1) · OHSU Knight Cancer Institute (1)
United States (4) · France (1) · Germany (1) · India (1)
Axel Hauschild, MD (1) · James Lowder, MD (1) · Jens Ulrich, MD (1) · Peter Mohr, MD (1) · Rajat Thawani (1) · Sapna Patel, MD (1) · Tharak Rao, MD (1) · William Sharfman, MD (1)